Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
about
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and painNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseAdenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout miceThe role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout miceG protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Room-temperature super-extraction system (RTSES) optimizes the anxiolytic- and antidepressant-like behavioural effects of traditional Xiao-Yao-San in mice.Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's DiseaseAdenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism.A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy personsAdenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease.Present and future drug treatment for Parkinson's disease.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseNovel investigational adenosine A2A receptor antagonists for Parkinson's disease.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Adenosine A2A antagonists in Parkinson's disease: what's next?Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Investigational approaches to therapies for restless legs syndrome.Advances in non-dopaminergic treatments for Parkinson's diseaseEfficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats.
P2860
Q24657796-5CD29C4E-A657-4572-AB98-7712BDB3A318Q24676705-641C9C6D-5203-4E6F-A5D1-4F9D88A8894FQ27301283-B7335AEF-2650-4198-A432-5A84D53AFEA2Q28346715-A97A084B-82A9-4502-8FA2-939570CD4EA3Q28348761-4500FA98-F216-4A21-B226-E8EE913AFC25Q30385233-A650E9AC-DA1E-4125-B46B-609DA0FCB307Q30457889-EAE09DD7-EE55-4CE0-BE35-9D61C39AE6E7Q30472044-436CEB34-2ABE-4020-AB0E-488559A9C8CBQ30482913-31836DB6-FDDB-437C-B6AA-3BDA9C690D1BQ33591302-E7D33A6D-8816-40A4-9C5C-F44ACC767A4CQ34341756-D11FE9AF-BF0B-43FD-87CB-D172E62199B9Q34414817-0AE85345-26F9-4CDD-A9E2-58F1D08488E9Q34509861-FB59CC3F-3D1A-4A54-9E22-8A76576D5A57Q34547466-23D8845E-BFAF-406F-A499-B36C49A7903EQ35036220-A6D47F4B-DDE5-4C56-8647-2F4E3F0F7540Q35484805-1D3E36D1-DA2A-4A24-9705-70B3A522205CQ35489240-EE1D0200-F4A7-4270-9C2C-1F29AB8A0E79Q35589979-006779B5-5573-41A8-B08D-68A13EB474BAQ35607243-C4C797EF-9ECD-4C00-8EF7-C65CA1DBB7B6Q36882447-F0BEAD1B-0972-435B-BF95-C7ACD9B12387Q37348458-DEB1789D-9EA5-42B0-81C5-8DB592D36699Q37358676-9EBF82E6-35CE-427A-88DD-39D97640FAB5Q37627259-DE2D3111-B6A1-40C0-A811-6689EA10FE99Q37844573-1B44A4A7-6DF6-4BFA-990D-C15EEC8FBDE5Q37852727-DE365D57-528F-4799-B55D-D3CBBC222A28Q37963718-96623B39-5CC3-4664-AA67-D848947EC4D9Q37974709-573837FF-8FA8-4577-A9D9-22E1DB3F4FFEQ38010070-32684803-1B4C-4629-92D3-D4F4FDE7171DQ38092819-A547377A-D4AE-47FB-988E-E853DAA09809Q38169996-3DCC4FEF-6911-474C-82F5-73CBA3E13EEAQ38170421-B05479FA-36DC-461A-8932-E0D64012E075Q38199744-CB4EEC9D-37D9-441E-8E44-88A730E4137FQ38200930-79B0511A-4C5A-4151-B4C6-17C482DB8889Q38202686-BF0B1993-04A7-47B1-B00B-AA41A661BCB0Q38218083-D9D2E645-E959-4EC9-8F44-B248A66CC7A0Q38237288-7F767151-7F25-4D20-906A-63460927A9C1Q42135362-933AB814-0A4E-41D1-8955-0ABFF393CF60Q43635686-AF9B54DA-52D9-4DEA-A8AE-B7CB8F27DDB3Q43795840-597C91A7-1583-4E6A-A102-EEA966554C88Q43825588-42E76121-F163-4D90-9D14-1D77649639D8
P2860
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@ast
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@en
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@nl
type
label
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@ast
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@en
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@nl
prefLabel
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@ast
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@en
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@nl
P2093
P356
P1433
P1476
Actions of adenosine A2A recep ...... ia caused by reserpine or MPTP
@en
P2093
P2888
P356
10.1007/S002130051146
P407
P577
1999-11-01T00:00:00Z
P6179
1025709890